Andy Forman focuses his antitrust practice on high-stakes merger clearances, civil antitrust investigations, and counseling.

Andy draws on decades of experience as a former Deputy Assistant Attorney General at the US Department of Justice’s (DOJ’s) Antitrust Division (2022–2025), at the Federal Trade Commission, and over 15 years in private practice to help clients navigate a broad spectrum of competition matters, including:

  • Mergers and acquisitions
  • Joint ventures
  • Conduct investigations
  • Antitrust litigation

Andy has experience across a wide range of industries, including technology, healthcare and life sciences, pharmaceuticals, insurance, finance and fintech, transportation, consumer products, entertainment, housing, building products, industrials, aerospace, and defense.

Andy is recognized in the industry as a leading antitrust lawyer. His work includes helping lead teams that received recognition on multiple occasions from Global Competition Review’s for “Matter of the Year” and other awards. He or his teams also have been recognized by The Legal 500 US, Best Lawyers in America, and Benchmark Litigation.

Prior to joining Latham, Andy represented leading companies, including: Elanco, Nucor, and US Airways Inc.

Some representative matters include:

  • Elanco Animal Health Incorporated in its US$7.6 billion acquisition of the animal health business of Bayer AG*
  • Uber in its US$2.65 billion acquisition of Postmates*
  • Hexion in its US$425 million sale of certain resins businesses*
  • PRA Health Sciences in its US$12 billion sale to ICON*
  • The Medicines Company in its US$9.7 billion sale to Novartis AG*
  • Smith & Nephew in its acquisition of Osiris Therapeutics*
  • JACK Entertainment LLC in multiple transactions*
  • Sirius XM in connection with a DOJ antitrust investigation regarding its US$3.5 billion acquisition of Pandora Media*
  • CSRA in its US$9.7 billion acquisition by General Dynamics*
  • Dana Incorporated in its approximately US$6.1 billion definitive agreement to combine with the Driveline division of GKN plc to create Dana plc*
  • ARIAD Pharmaceuticals, Inc. in its approximately US$5.2 billion acquisition by Takeda Pharmaceutical Company Limited*
  • Aer Lingus in International Airline Group’s US$1.4 billion offer for Aer Lingus*
  • Nucor Corporation in evaluating potential antitrust considerations in various potential transactions
  • Salix Pharmaceuticals, Ltd.:
    • In its US$15.6 billion acquisition by Valeant Pharmaceuticals International, Inc.*
    • In its proposed transaction with Cosmo Technologies*
  • US Airways, Inc.:
    • In its US$17 billion merger with American Airlines
    • In its slot transaction with Delta Air Lines
    • In numerous other antitrust matters
  • Virtu Financial, Inc. in its approximately US$1.4 billion acquisition of KCG Holdings*
  • Vertis Holdings, Inc., an advertising and direct mail company, in its bankruptcy sale to rival Quad/Graphics, Inc.*
  • Élan Corporation PLC in the US$3.3 billion sale of its multiple sclerosis joint venture interest to Biogen Idec, Inc.*
  • Pfizer Inc. in its US$68 billion acquisition of Wyeth Pharmaceuticals*
  • Microsoft Corporation in numerous antitrust matters*
  • Anheuser-Busch InBev in various antitrust matters*
  • Goodyear Tire & Rubber Company in various antitrust matters*

*Matter handled prior to joining Latham

Bar Qualification

  • District of Columbia
  • Maryland

Education

  • JD, Georgetown University Law Center, 2000
    cum laude
  • BA, Washington University, 1995